Literature DB >> 17545690

Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.

Pardeep Kaurah1, Andrée MacMillan, Niki Boyd, Janine Senz, Alessandro De Luca, Nicki Chun, Gianpaolo Suriano, Sonya Zaor, Lori Van Manen, Cathy Gilpin, Sarah Nikkel, Mary Connolly-Wilson, Scott Weissman, Wendy S Rubinstein, Courtney Sebold, Robert Greenstein, Jennifer Stroop, Dwight Yim, Benoit Panzini, Wendy McKinnon, Marc Greenblatt, Debrah Wirtzfeld, Daniel Fontaine, Daniel Coit, Sam Yoon, Daniel Chung, Gregory Lauwers, Antonio Pizzuti, Carlos Vaccaro, Maria Ana Redal, Carla Oliveira, Marc Tischkowitz, Sylviane Olschwang, Steven Gallinger, Henry Lynch, Jane Green, James Ford, Paul Pharoah, Bridget Fernandez, David Huntsman.   

Abstract

CONTEXT: Hereditary diffuse gastric cancer is caused by germline mutations in the epithelial cadherin (CDH1) gene and is characterized by an increased risk for diffuse gastric cancer and lobular breast cancer.
OBJECTIVE: To determine whether recurring germline CDH1 mutations occurred due to independent mutational events or common ancestry. DESIGN, SETTING, AND PATIENTS: Thirty-eight families diagnosed clinically with hereditary diffuse gastric cancer were accrued between November 2004 and January 2006 and were analyzed for CDH1 mutations as part of an ongoing study at the British Columbia Cancer Agency. Twenty-six families had at least 2 gastric cancer cases with 1 case of diffuse gastric cancer in a person younger than 50 years; 12 families had either a single case of diffuse gastric cancer diagnosed in a person younger than 35 years or multiple cases of diffuse gastric cancer diagnosed in persons older than 50 years. MAIN OUTCOME MEASURES: Classification of family members as carriers or noncarriers of CDH1 mutations. Haplotype analysis to assess recurring mutations for common ancestry was performed on 7 families from this study and 7 previously reported families with the same mutations.
RESULTS: Thirteen mutations (6 novel) were identified in 15 of the 38 families (40% detection rate). The 1137G>A splicing mutation and the 1901C>T (A634V) missense/splicing mutation occurred on common haplotypes in 2 families but on different haplotypes in a third family. The 2195G>A (R732Q) missense/splicing mutation occurred in 2 families on different haplotypes. The 2064-2065delTG mutation occurred on a common haplotype in 2 families. Two families from this study plus 2 additional families carrying the novel 2398delC mutation shared a common haplotype, suggesting a founder effect. All 4 families originate from the southeast coast of Newfoundland. Due to concentrations of lobular breast cancer cases, 2 branches of this family had been diagnosed as having hereditary breast cancer and were tested for BRCA mutations. Within these 4 families, the cumulative risk by age 75 years in mutation carriers for clinically detected gastric cancer was 40% (95% confidence interval [CI], 12%-91%) for males and 63% (95% CI, 19%-99%) for females and the risk for breast cancer in female mutation carriers was 52% (95% CI, 29%-94%).
CONCLUSIONS: Recurrent CDH1 mutations in families with hereditary diffuse gastric cancer are due to both independent mutational events and common ancestry. The presence of a founder mutation from Newfoundland is strongly supported.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545690     DOI: 10.1001/jama.297.21.2360

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  139 in total

Review 1.  A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer.

Authors:  Rajini Seevaratnam; Natalie Coburn; Roberta Cardoso; Matthew Dixon; Alina Bocicariu; Lucy Helyer
Journal:  Gastric Cancer       Date:  2011-12-10       Impact factor: 7.370

Review 2.  Quality of life: A critical outcome for all surgical treatments of gastric cancer.

Authors:  Michael D McCall; Peter J Graham; Oliver F Bathe
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 3.  Recognition of and recent issues in hereditary diffuse gastric cancer.

Authors:  Shinya Sugimoto; Hirokazu Komatsu; Yuichi Morohoshi; Takanori Kanai
Journal:  J Gastroenterol       Date:  2015-06-07       Impact factor: 7.527

4.  Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC).

Authors:  Winifred Lo; Bin Zhu; Arvind Sabesan; Ho-Hsiang Wu; Astin Powers; Rebecca A Sorber; Sarangan Ravichandran; Ina Chen; Lucas A McDuffie; Humair S Quadri; Joal D Beane; Kathleen Calzone; Markku M Miettinen; Stephen M Hewitt; Christopher Koh; Theo Heller; Sholom Wacholder; Udo Rudloff
Journal:  J Med Genet       Date:  2019-02-11       Impact factor: 6.318

5.  Mutation screen and RNA analysis disclose the changed splicing of the E-cadherin transcription in gastric cancer.

Authors:  Xiaowei Li; Yafan Gao; Yiyuan Pan; Yan Pan; Lifeng Wang; Nong Xiao; Qiong He; Yimei Fan; Yaping Wang
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

6.  Novel CDH1 germline mutations identified in Chinese gastric cancer patients.

Authors:  Qin-Hua Chen; Wei Deng; Xiao-Wei Li; Xiu-Fang Liu; Jing-Mei Wang; Li-Feng Wang; Nong Xiao; Qiong He; Ya-Ping Wang; Yi-Mei Fan
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 7.  The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.

Authors:  Anosheh Afghahi; Allison W Kurian
Journal:  Curr Treat Options Oncol       Date:  2017-05

8.  Germline mutations in hereditary diffuse gastric cancer.

Authors:  Hao Zhang; Mengmeng Feng; Yi Feng; Zhaode Bu; Ziyu Li; Shuqin Jia; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

9.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

Review 10.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.